In this episode, we explore the complex management of Giant Omphalocele, comparing surgical options like staged silo repair against the conservative "paint and wait" strategy used to manage viscero-abdominal disproportion. We discuss critical comorbidities that dictate prognosis, including pulmonary hypoplasia, Beckwith-Wiedemann syndrome, and rare defects like Pentalogy of Cantrell. Finally, we examine evolving techniques such as the DuoDerm® silo and Component Separation Technique, alongside new data regarding long-term neurodevelopmental risks, including autism spectrum disorder.

In this episode, we explore the rapidly evolving landscape of Multiple Myeloma management in 2025, highlighting the shift from reactive diagnostic methods to the proactive SLiM-CRAB criteria. We discuss the development of the 'Real-World International Staging System' (RW-ISS), which incorporates patient age and performance status to refine prognosis prediction outside of clinical trials. The episode covers major therapeutic milestones, including the FDA approval of the bispecific antibody linvoseltamab (Lynozyfic) and the re-emergence of the antibody-drug conjugate belantamab mafodotin (Blenrep) for relapsed/refractory disease. Finally, we examine pivotal research presented at ASH 2025, specifically how CAR T-cell therapies like cilta-cel are moving into earlier lines of treatment and the potential for GLP-1 agonists to lower progression risk in precursor conditions like MGUS.

In this episode, we explore the rapidly evolving landscape of Huntington’s disease (HD), from the mechanics of the HTT gene’s CAG repeat expansion to the phenomenon of somatic instability, where the mutation grows in specific tissues over time. We discuss the latest therapeutic breakthroughs, including uniQure’s AMT-130 gene therapy, which recently demonstrated a potential 75% slowing of disease progression, alongside the regulatory challenges facing its approval. Finally, we examine the profound ethical dilemmas of predictive genetic testing and the critical role of the Enroll-HD observational study in accelerating research.

In this episode, we examine Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD), the most common fatty acid oxidation disorder, which prevents the body from breaking down fat stores into energy during periods of fasting or illness. We discuss the lifesaving impact of newborn screening via tandem mass spectrometry to detect elevated octanoylcarnitine (C8), the condition's genetic basis in the ACADM gene, and the critical management strategy of strict fasting avoidance and emergency glucose protocols. Finally, we explore long-term health outcomes, including potential speech and motor delays despite early diagnosis, as well as pregnancy risks such as HELLP syndrome in carriers carrying an affected fetus.

In this episode, we examine the aggressive nature of Small Cell Lung Cancer (SCLC), covering its four molecular subtypes and the evolving treatment landscape from standard chemotherapy to novel immunotherapies and antibody-drug conjugates. We also discuss the prognostic importance of TNM staging, recent FDA approvals such as tarlatamab, and essential resources for patient support.

In this episode, we explore Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive haematologic malignancy that typically manifests with distinctive skin lesions alongside bone marrow and lymph node involvement. We discuss the diagnostic process, highlighting the essential '123456' immunophenotype (CD123, CD4, CD56) and the high frequency of occult central nervous system disease, which necessitates specific screening. Finally, we review the therapeutic landscape, including the approved CD123-targeted agent tagraxofusp, the use of acute lymphoblastic leukaemia-type chemotherapy regimens, the critical role of stem cell transplantation for durable remission, and promising emerging treatments such as pivekimab sunirine.

In this episode, we explore the clinical and molecular complexities of Stickler syndrome, the leading cause of hereditary retinal detachment and a common cause of cleft palate. We discuss the phenotypic variability across subgroups—from the high-risk COL2A1 Type 1 to the non-ocular COL11A2 Type 3—and the critical role of vitreous phenotyping and genetic testing in diagnosis. We also examine management strategies, including the efficacy of prophylactic retinopexy for preventing blindness, the treatment of associated Pierre Robin sequence and early-onset arthropathy, and the differential diagnosis from allied disorders like Marshall and Wagner syndromes.

In this episode, we dive into Steinert myotonic dystrophy (DM1), a multisystemic genetic disorder caused by a CTG repeat expansion in the DMPK gene that leads to toxic RNA buildup. We explore the latest breakthroughs in disease-modifying therapies, including positive clinical trial data from Avidity Biosciences’ del-desiran and Dyne Therapeutics’ DYNE-101, which have shown potential to reverse disease progression and improve muscle function. Finally, we highlight the unification of over 60 organizations under the Global Alliance for Myotonic Dystrophy Awareness to boost clinical trial readiness for Rare Disease Day 2025.

In this episode, we explore the paradigm shift in Hypermobile Ehlers-Danlos Syndrome (hEDS), moving from a diagnosis of exclusion to a complex condition driven by newly identified genetic risk loci near the ACKR3 and SLC39A13 genes and variants in the Kallikrein gene family. We discuss ground-breaking 2025 research that redefines hEDS as a "neuroimmune-stromal" disorder, offering a biological explanation for the debilitating "trifecta" of joint hypermobility, Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Finally, we cover essential clinical management strategies, including the stabilization-focused Muldowney Physical Therapy Protocol and critical surgical considerations regarding tissue fragility and local anesthetic resistance.

In this episode, we explore Addison’s disease, a life-threatening condition where the adrenal glands fail to produce sufficient cortisol and aldosterone,. We break down the clinical signs—including fatigue, hyperpigmentation, and salt cravings,—and the critical "sick day rules" patients must follow to prevent a fatal adrenal crisis,. Finally, we discuss the latest advancements in treatment, such as modified-release hydrocortisones designed to mimic natural circadian rhythms, and emerging research into stem cell therapies and adrenal transplantation,.